1-4 of 4
Sandra Dai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-134437
Published: 2020
Journal Articles

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Paul M. Barr, MD, Alessandra Tedeschi, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Jennifer Woyach, MD, John C. Byrd, MD, Paolo Ghia, MD PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Sandra Dai, PhD MS, Carlos Amaya-Chanaga, MD, James P. Dean, MD PhD, Susan M. o'Brien, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3054.
https://doi.org/10.1182/blood-2019-123327
Published: 2019
Journal Articles

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Clinical Trials & Observations
John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James, Jennifer R. Brown
Journal: Blood
Blood (2019) 133 (19): 2031–2042.
https://doi.org/10.1182/blood-2018-08-870238
Published: 2019
Includes: Supplemental data
Journal Articles

Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study

Alessandra Tedeschi, MD, Carolyn Jane Owen, MD FRCPC, Tadeusz Robak, MD PhD, Paul M. Barr, MD, Osnat Bairey, MD, Peter Hillmen, MBChB, PhD, Steven Coutre, MD, Stephen Devereux, FRCP, FRCPath, PhD, Sebastian Grosicki, MD PhD, Helen McCarthy, MBBS, PhD, Jianyong Li, MD, David Simpson, MBChB, Tanya Siddiqi, MD, Giri Iyer, MBA, Indu D. Lal, MD, Jeremiah Trudeau, PhD, Sandra Dai, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jan A. Burger, MD PhD, Paolo Ghia, MD PhD, Thomas J. Kipps, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1746.
https://doi.org/10.1182/blood.V130.Suppl_1.1746.1746
Published: 2017